Prurigo Nodularis clinical trials at UCSF
1 in progress, 0 open to eligible people
Sorry, in progress, not accepting new patients
To investigate the anti-pruritic efficacy and safety of Nalbuphine ER (NAL ER) tablets in Prurigo Nodularis. Subjects will be randomized to NAL ER (or matching placebo) with the primary endpoint evaluation at Week 14. During the open label extension, subjects who received NAL ER will continue on NAL ER and subjects who received placebo will crossover to NAL ER.
San Francisco, California and other locations
Our lead scientists for Prurigo Nodularis research studies include Timothy Berger.